基本介紹
- 中文名：許岳慷
- 學位/學歷：博士
- 職業：教師
- 專業方向：免疫細胞的信號傳導
- 任職院校：安徽師範大學
個人經歷,研究方向,學術成果,榮譽獎項,
個人經歷
1985年7月在安徽醫科大學獲醫學學士學位，1987年7月在安徽師範大學獲文學學士學位。畢業後在安徽醫科大學及安徽省醫學遺傳中心工作。1998年6月赴澳大利亞做訪問學者，2004年4月在墨爾本大學獲哲學博士學位。在澳先後從事博士後、研究官員及研究員工作。現為安徽師範大學特聘教授。
澳亞免疫協會會員
· 安徽省細胞生物學學會常務理事
· 安徽省免疫學會理事
研究方向
·免疫細胞的信號傳導：當外界病原微生物侵入機體時，免疫細胞首先做出反應。本實驗室主要研究免疫細胞在受到炎性刺激後，胞內信號通路中哪些分子發生了變化，這些變化最終如何改變免疫細胞功能和行為，以及根據這些變化找到併合成該分子的類似物或拮抗劑以控制炎性信號的發展，從而達到臨床治療的目的。
·炎性樹突狀細胞的發育和功能：樹突狀細胞在免疫反應中起著支配和主導作用。不同的生長因子和生長環境控制產生不同的樹突狀細胞。本實驗室主要研究在炎症條件下樹突狀細胞的發育過程中哪些因素通過什麼方式控制產生了什麼類型的樹突狀細胞，這些樹突狀細胞功能上有什麼區別，能主導著什麼樣的免疫反應，以及我們能否利用這些因素在體外定向生產這種樹突狀細胞回輸體內干預免疫反應。
·免疫生化：樹突狀細胞不僅調節免疫應答而且大量產生胱抑素C。胱抑素C是一種蛋白酶抑制劑，控制著組織基質內蛋白溶酶的活性。同時它也是一種纖維化蛋白，可在血管內形成纖維沉澱而破壞血管內壁。本實驗室主要研究哪些因素可以調節胱抑素C的分泌，哪些因素會誘導胱抑素C纖維化的形成及分泌，以及這些因素是否可以被用於臨床來治療因蛋白溶酶活性過高、過低或胱抑素C纖維化而導致的疾病（如動脈粥樣硬化和阿茲海默症等）。
學術成果
國家自然科學基金重大研究計畫項目、血管組織DC的區域免疫特性及抑炎機制、91742101、國家基金委、主持。
· 安徽省對外科學技術合作項目、炎症條件下樹突狀細胞發育和功能的分子機制研究、1604b0602017、安徽省科技廳、主持。
· 安徽省自然基金面上項目、胱抑素C調控在血管內膜損傷機制中的研究、1608085MH160、安徽省自然科學基金委員會、主持。
· 澳大利亞國立衛生醫學研究委員會項目基金、Regulation of Cardiovascular Disease-Associated Protease Inhibitor Cystatin C for Therapeutic Application、1006428、主持。
· 澳大利亞國立衛生醫學研究委員會Peter Doherty基金、Improving Anti-Tumor Therapy by Genetically Modifying CD4 T cells、400426、主持。
· 美國Susan Komen基金、Genetic Modification of Multiple Immune System Cells for Breast Cancer Therapy、PDF39606、主持。
· Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, Herold MJ, Huntington ND, Lew AM, Xu Y*, Zhan Y. GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function. Front Immunol. 2018 Aug 28;9:1922. doi: 10.3389/fimmu.2018.01922. eCollection 2018.
· W. Zhang, Y Ding, L. Sun, Q. Hong, Y. Sun, L. Han, M. Zi, Y. Xu*, Bone marrow-derived inflammatory and steady state DCs are different in both functions and survival. Cell Immunol, 331,100-109 (2018).
· S. Chen, X. Li, W. Zhang, M. Zi, Y. Xu*, Inflammatory compound lipopolysaccharide promotes the survival of GM-CSF cultured dendritic cell via PI3 kinase-dependent upregulation of Bcl-x. Immunol Cell Biol, doi: 10.1111/imcb.12051. [Epub ahead of print] (2018).
· Zi M, Xu, Y*. Involvement of cystatin C in immunity and apoptosis. Immunol Lett. 196:80-90, 2018
· X Li, Y Ding, M Zi, L Sun, W Zhang, S Chen, Y Xu*：CD19, from bench to bedside. Immunol Lett, 183:86-95.2017
· Xu, Y*, Ding, Y., Li, X., and Wu, X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol. 93(5):442-51.2015
· Xu Y*, Lindemann P, Vega-Ramos J, Zhang JG, Villadangos JA. Developmental Regulation of Synthesis and Dimerization of the Amyloidogenic Protease inhibitor Cystatin C in the Hematopoietic System. J Biol Chem. 289(14):9730-40. 2014.
· Xu Y*, Fairfax K, Light A, Huntington ND, Tarlinton DM. CD19 Differentially Regulates BCR Signalling through the Recruitment of PI3K. Autoimmunity. 2014 Jun 23:1-8. [Epub ahead of print].
· Xu W, Pan H, Xu Y*, and Ye D. Interferon Regulatory Factor 5 and Autoimmune Lupus. Expert Rev Mol Med. 10.1017/erm2013.7. 2013. (*senior author)
· Li B, Ye Q, Xu W, Li J, Ye D and Xu Y*. GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity. 46:409. 2013.
· Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM and Xu Y*. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol. 42:2889. 2012.
· Xu WD. Pan HF, Ye DQ, and Xu Y*. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11:918. 2012.
· Xu Y, Huntington ND, Harder K, Nandurkar H, Hibbs ML and Tarlinton. Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase. Immunol Cell Biol. 90:903. 2012
· Xu Y*, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea H, Dickins RA and Villadangos JA. Interleukin-10 Controls Cystatin C Synthesis and Blood Concentration in Response to Inflammation through Regulation of IRF-8 Expression. J. Immunol. 186:3666 (2011).
· Xu Y*, Zhan Y, Lew AM, Naik SH and Kershaw MH. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol 179(11):7577-84 (2007).
· Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, Strasser A, Tarlinton DM. CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers. Nat. Immunol. 7(2):190-8. (2006).
· Xu Y, Harder KW, Huntington ND, Hibbs ML, and Tarlinton DM. Lyn tyrosine kinase：accentuating the positive and the negative. Immunity. 22:9-18 (2005).
· Huntington ND, Xu Y, Nutt S, Tarlinton DM. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary NK cells. J. Exp. Med. 201:1421-33 (2005).
· Xu Y, Davies J, Ramsland P, Holmdahl R, Kumar N, Scealy M, Rowley M. Two monoclonal antibodies to precisely the same epitope of type II collagen select non-crossreactive phage clones by phage display：implications for autoimmunity and molecular mimicry. Mol. Immunol. 41:411-9 (2004).
· Xu Y, Beavitt SJ, Harder KW, Hibbs ML, Tarlinton DM. The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent. J. Immunol. 169:6910-8 (2002).
榮譽獎項
ICB Publications of the Year Runner Up Awards, Australia
· NHMRC Project Grant (APP1006428, CIA), Australia.
· International Postdoctoral Travel Award from Australian Society of Immunology, Australia.
· International Travel Bursary from 4th Congress of the Federation of Immunology Societies of Asia-Oceania (FIMSA), Taipei, Taiwan.
· International Travel Award from Australian Society of Immunology.
· NHMRC Peter Doherty Fellowship, Australia.
· Susan Komen Postdoctoral Fellowship, Susan Komen Foundation, US.
